Vera Therapeutics, Inc.
VERA
$34.25
-$1.03-2.92%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 33.97% | 12.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.10% | 32.83% | |||
| Operating Income | 10.10% | -32.83% | |||
| Income Before Tax | 9.55% | -32.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.55% | -32.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.55% | -32.86% | |||
| EBIT | 10.10% | -32.83% | |||
| EBITDA | 10.11% | -32.87% | |||
| EPS Basic | 10.00% | -21.99% | |||
| Normalized Basic EPS | 9.71% | -21.84% | |||
| EPS Diluted | 10.00% | -21.99% | |||
| Normalized Diluted EPS | 9.71% | -21.84% | |||
| Average Basic Shares Outstanding | 0.51% | 8.92% | |||
| Average Diluted Shares Outstanding | 0.51% | 8.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||